Edwards Lifesciences Corp (NYSE:EW) Expected to Announce Earnings of $1.48 Per Share

Wall Street analysts expect that Edwards Lifesciences Corp (NYSE:EW) will announce earnings per share (EPS) of $1.48 for the current quarter, Zacks Investment Research reports. Eight analysts have provided estimates for Edwards Lifesciences’ earnings, with the highest EPS estimate coming in at $1.53 and the lowest estimate coming in at $1.45. Edwards Lifesciences posted earnings per share of $1.17 during the same quarter last year, which indicates a positive year-over-year growth rate of 26.5%. The company is scheduled to report its next quarterly earnings results on Thursday, January 30th.

On average, analysts expect that Edwards Lifesciences will report full-year earnings of $5.60 per share for the current fiscal year, with EPS estimates ranging from $5.57 to $5.65. For the next financial year, analysts anticipate that the business will report earnings of $6.15 per share, with EPS estimates ranging from $5.91 to $6.38. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Edwards Lifesciences.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Wednesday, October 23rd. The medical research company reported $1.41 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.19. Edwards Lifesciences had a net margin of 18.64% and a return on equity of 32.28%. The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the prior year, the firm posted $1.07 EPS. The company’s revenue for the quarter was up 20.7% compared to the same quarter last year.

Several equities analysts recently issued reports on EW shares. ValuEngine lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. UBS Group boosted their price objective on Edwards Lifesciences from $205.00 to $230.00 and gave the company a “neutral” rating in a research note on Wednesday, October 16th. Cowen upped their target price on Edwards Lifesciences from $250.00 to $265.00 and gave the company a “positive” rating in a research report on Thursday, October 24th. Credit Suisse Group upped their target price on Edwards Lifesciences from $226.00 to $261.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. Finally, Canaccord Genuity raised their target price on Edwards Lifesciences from $250.00 to $260.00 and gave the stock a “buy” rating in a research note on Thursday, October 24th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and thirteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $229.72.

Shares of NYSE EW opened at $242.85 on Tuesday. Edwards Lifesciences has a twelve month low of $139.64 and a twelve month high of $247.64. The firm has a fifty day simple moving average of $236.44 and a 200 day simple moving average of $210.72. The company has a market capitalization of $51.09 billion, a PE ratio of 51.67, a P/E/G ratio of 2.96 and a beta of 0.80. The company has a quick ratio of 2.74, a current ratio of 3.53 and a debt-to-equity ratio of 0.17.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

In other news, VP Huimin Wang sold 4,650 shares of Edwards Lifesciences stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $222.06, for a total transaction of $1,032,579.00. Following the completion of the transaction, the vice president now directly owns 36,898 shares in the company, valued at $8,193,569.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Scott B. Ullem sold 7,500 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $225.74, for a total transaction of $1,693,050.00. Following the sale, the chief financial officer now directly owns 21,064 shares of the company’s stock, valued at $4,754,987.36. The disclosure for this sale can be found here. In the last quarter, insiders sold 131,301 shares of company stock worth $30,331,718. Corporate insiders own 1.63% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in EW. Prestige Wealth Management Group LLC grew its holdings in Edwards Lifesciences by 32.8% during the third quarter. Prestige Wealth Management Group LLC now owns 466 shares of the medical research company’s stock worth $102,000 after buying an additional 115 shares in the last quarter. Bank of Hawaii purchased a new position in Edwards Lifesciences during the 3rd quarter worth $593,000. IHT Wealth Management LLC boosted its holdings in Edwards Lifesciences by 38.1% during the 3rd quarter. IHT Wealth Management LLC now owns 1,512 shares of the medical research company’s stock worth $333,000 after acquiring an additional 417 shares during the last quarter. GQ Asset Management LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth $259,000. Finally, National Pension Service grew its stake in shares of Edwards Lifesciences by 4.8% in the 3rd quarter. National Pension Service now owns 272,156 shares of the medical research company’s stock worth $59,850,000 after acquiring an additional 12,368 shares in the last quarter. Institutional investors and hedge funds own 80.87% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Story: Golden Cross

Get a free copy of the Zacks research report on Edwards Lifesciences (EW)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Leave a Reply

Your email address will not be published. Required fields are marked *

*